TW201612518A - Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody - Google Patents

Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody

Info

Publication number
TW201612518A
TW201612518A TW104101589A TW104101589A TW201612518A TW 201612518 A TW201612518 A TW 201612518A TW 104101589 A TW104101589 A TW 104101589A TW 104101589 A TW104101589 A TW 104101589A TW 201612518 A TW201612518 A TW 201612518A
Authority
TW
Taiwan
Prior art keywords
antagonist anti
treatment
benefit
fgfr4
liver cancer
Prior art date
Application number
TW104101589A
Other languages
English (en)
Inventor
Herbert Corentin
Genevieve Gueguen-Dorbes
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TW201612518A publication Critical patent/TW201612518A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW104101589A 2014-01-17 2015-01-16 Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody TW201612518A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14305065 2014-01-17

Publications (1)

Publication Number Publication Date
TW201612518A true TW201612518A (en) 2016-04-01

Family

ID=50002652

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104101589A TW201612518A (en) 2014-01-17 2015-01-16 Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody

Country Status (2)

Country Link
TW (1) TW201612518A (zh)
WO (1) WO2015107171A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
RU2742033C2 (ru) 2016-11-02 2021-02-01 Новартис Аг Комбинации ингибиторов fgfr4 и секвестрантов желчных кислот
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN111471109B (zh) * 2020-04-08 2021-07-23 中国科学院深圳先进技术研究院 一种抗成纤维细胞生长因子受体4单克隆抗体及其制备方法和用途
KR20240006519A (ko) * 2021-04-30 2024-01-15 온코씨4, 아이앤씨. 항-siglec 조성물 및 이의 용도
CN115778961B (zh) * 2022-11-11 2024-01-26 中国人民解放军空军军医大学 Pd173074在制备抗瘙痒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918376A1 (en) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
JP5570218B2 (ja) * 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4

Also Published As

Publication number Publication date
WO2015107171A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
AU2019229353A1 (en) Mutant calreticulin for the diagnosis of myeloid malignancies
TW201612518A (en) Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-FGFR4 antibody
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
MY167390A (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
MX2021006626A (es) Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl).
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
MX2016001439A (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
PH12017501064A1 (en) Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor
WO2015168617A3 (en) Compositions and methods for modulating mtorc1
MX2022001801A (es) Secuencias recombinantes de cromosoma b de maiz y sus usos.
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
PL410049A1 (pl) Sposób wykrywania zwiększonego ryzyka zachorowania na raka skóry oraz zastosowania genotypowego wariantu genu GRHL3
UA95978U (uk) Спосіб прогнозування зрощення перелому
UA95657U (uk) Спосіб прогнозування зрощення перелому
UA104421U (uk) Спосіб прогнозування зрощення перелому
UA95656U (uk) Спосіб прогнозування зрощення перелому
UA96595U (uk) Спосіб прогнозування зрощення перелому
TN2014000211A1 (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
UA104426U (uk) Спосіб прогнозування зрощення перелому
UA96639U (uk) Спосіб прогнозування зрощення перелому